KIT and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is a FDA-approved treatment for gastrointestinal stromal tumors which are driven by c-KIT mutations in >80% of cases, chronic myelogenous leukemia where it targets the aberrant BCR-ABL kinase, and in select metastatic melanoma tumors with activating c-KIT mutations [73,74,75].